Division of Nephrology, Miulli General Hospital, 70021, Acquaviva delle Fonti, Italy.
Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy.
J Nephrol. 2021 Apr;34(2):365-368. doi: 10.1007/s40620-021-01002-4. Epub 2021 Mar 8.
The COVID-19 pandemic has resulted in major disruption to the delivery of both routine and urgent healthcare needs in many institutions across the globe. Vascular access (VA) for haemodalysis (HD) is considered the patient's lifeline and its maintenance is essential for the continuation of a life saving treatment. Prior to the COVID-19 pandemic, the provision of VA for dialysis was already constrained. Throughout the pandemic, inevitably, many patients with chronic kidney disease (CKD) have not received timely intervention for VA care. This could have a detrimental impact on dialysis patient outcomes in the near future and needs to be addressed urgently. Many societies have issued prioritisation to allow rationing based on clinical risk, mainly according to estimated urgency and need for treatment. The recommendations recently proposed by the European and American Vascular Societies in the COVID-19 pandemic era regarding the triage of various vascular operations into urgent, emergent and elective are debatable. VA creation and interventions maintain the lifeline of complex HD patients, and the indication for surgery and other interventions warrants patient-specific clinical judgement and pathways. Keeping the use of central venous catheters at a minimum, with the goal of creating the right access, in the right patient, at the right time, and for the right reasons, is mandatory. These strategies may require local modifications. Risk assessments may need specific "renal pathways" to be developed rather than applying standard surgical risk stratification. In conclusion, in order to recover from the second wave of COVID-19 and prepare for further phases, the provision of the best dialysis access, including peritoneal dialysis, will require working closely with the multidisciplinary team involved in the assessment, creation, cannulation, surveillance, maintenance, and salvage of definitive access.
新冠疫情大流行导致全球许多医疗机构的常规和紧急医疗需求的提供受到了重大干扰。血管通路(VA)是血液透析(HD)的生命线,其维护对于维持救命治疗至关重要。在新冠疫情之前,VA 为透析提供已经受到限制。在整个疫情期间,不可避免的是,许多慢性肾脏病(CKD)患者没有及时接受 VA 护理干预。这可能会对透析患者的近期结果产生不利影响,需要紧急解决。许多协会已经提出了优先排序,以便根据临床风险进行配给,主要是根据估计的紧急程度和治疗需求。欧洲和美国血管协会在新冠疫情期间提出的关于各种血管手术分类为紧急、紧急和择期的建议是有争议的。VA 的创建和干预维持着复杂 HD 患者的生命线,手术和其他干预的指征需要根据患者的具体情况进行临床判断和制定相应的路径。尽量减少中心静脉导管的使用,目标是在正确的患者、正确的时间、为正确的原因创建正确的通路,这是强制性的。这些策略可能需要进行局部修改。风险评估可能需要开发特定的“肾脏路径”,而不是应用标准的手术风险分层。总之,为了从第二波新冠疫情中恢复并为进一步阶段做好准备,提供最佳的透析通路,包括腹膜透析,需要与涉及评估、创建、插管、监测、维护和挽救确定性通路的多学科团队密切合作。